ClinicalTrials.gg
RecruitingNCT07445048Updated Apr 17, 2026

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

A Phase 3 interventional study of Bemcentinib and Nimotuzumab in Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer and Postoperative Adjuvant Treatment, sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
370
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Squamous Cell Carcinoma of Head and Neck by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University — 10 open to participants now, 12 under way, 4 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University.

Planned enrollment
2nd of 19
370 · median 81
Started
2026
with 3 others
Phase 3
3 of 20
3 open now
Primary completion
2028-03
later than 7 of 11 live
Registered
18th of 20
by date

Among the 20 studies in Squamous Cell Carcinoma of Head and Neck by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, this one is the 2nd largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 3, reaches primary completion later than 7 of the 11 other live ones, and was the 18th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

10 of the 20 studies in Squamous Cell Carcinoma of Head and Neck by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Squamous Cell Carcinoma of Head and Neck by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, or all of them as a file.
02

Study summary

A Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Trial.To evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab followed by Benmelstobart in high-risk patients with head and neck squamous cell carcinoma who are ineligible for cisplatin chemotherapy.

The primary endpoint is disease-free survival (DFS). A total of 185 patients will be enrolled in both the study group and the control group, respectively, with a total planned enrollment of 370 patients. Enrollment is expected to be completed within 2 years, followed by a 3-year follow-up period after the last patient is enrolled.

03

Conditions studied

  • Head & Neck Squamous Cell Carcinoma
  • Head & Neck Cancer
  • Postoperative Adjuvant Treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Patients ineligible for cisplatin chemotherapy, defined as meeting any of the following:① Age > 70 years;② Renal insufficiency ( \< 50 mL/min; criterion ⑩ below does not apply if this criterion is met);③ Severe tinnitus or hearing impairment (requiring hearing aid, or audiometry showing ≥ 25 dB loss at two consecutive frequencies);④ Unable to receive intravenous hydration (e.g., due to cardiac dysfunction or other comorbidities, as judged by the investigator);⑤ Neuropathy > Grade 1;⑥ Patient refusal of chemotherapy.
  3. confirmed locally advanced head and neck squamous cell carcinoma (AJCC 8th edition Stage III-IVB), including oral cavity cancer, HPV-negative/unrelated oropharyngeal cancer, hypopharyngeal cancer, and laryngeal cancer.
  4. Underwent radical surgery with at least one high-risk feature:

    Extracapsular extension (ECE) of lymph node ; Close margin (\< 1 mm) or positive margin;

    • 4 metastatic lymph nodes, or multiple perineural invasions.
  5. No evidence of distant metastasis on imaging.
  6. Sufficient tumor tissue available for EGFR and testing; for oropharyngeal cancer, HPV/p16 testing is required (testing may be waived if results are already available).
  7. Expected survival ≥ 6 months.
  8. performance status 0-1.
  9. Adequate hematologic function:

    WBC ≥ 3 × 10⁹/L; ≥ 1.5 × 10⁹/L; ≥ 100 × 10⁹/L; ≥ 90 g/L.

  10. Adequate renal function:Serum creatinine ≤ 1.5 × or creatinine clearance (CrCl) > 50 mL/min (calculated by Cockcroft-Gault formula):

    Female: CrCl = (140 - Age) × Weight (kg) × 0.85 / (72 × Scr (mg/dL)) Male: CrCl = (140 - Age) × Weight (kg) × 1.00 / (72 × Scr (mg/dL))

  11. Adequate hepatic function:

    Total ≤ 1.5 × ULN; ≤ 2.5 × ULN; ALT ≤ 2.5 × ULN.

  12. Women of : negative serum or urine pregnancy test within 14 days before enrollment, and agreement to use effective during the study.Male subjects: use effective contraception from the start of treatment until 180 days after the last study drug administration.
  13. Voluntary participation in the study, signed written , good compliance, and willingness to comply with follow-up procedures.

Exclusion criteria

exclusion Criteria:

  1. Prior radiotherapy for head and neck cancer before enrollment.
  2. Prior treatment with similar immunological or targeted agents.
  3. Participation in another interventional clinical trial within 30 days prior to screening.
  4. Evidence of distant .
  5. History of other within the previous 5 years, except cured carcinoma in situ of the cervix, non-melanoma skin cancer, localized differentiated thyroid cancer (papillary / follicular), localized prostate cancer, and ductal carcinoma in situ.
  6. Uncontrolled concurrent medical conditions (e.g., heart failure, diabetes mellitus, hypertension, thyroid disease, psychiatric disorders, etc.).
  7. Known infection, active viral hepatitis, or active tuberculosis.
  8. Major surgical procedure within 30 days before the first dose of study medication, or planned major surgery during the study.
  9. to any study drug or their components.
  10. Pregnancy (confirmed by serum or urine HCG test) or lactating women; subjects of unwilling or unable to use effective (for both male and female subjects) until at least 6 months after the last study treatment.
  11. Subjects considered inappropriate for study participation by the investigator.
  12. Subjects unwilling to participate in the study or unable to provide written .
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
370 participants (estimated)

Study arms

  • Experimental
    Study Group

    Drug: Bemcentinib · Drug: Nimotuzumab · Radiation: radiotherapy

  • Active comparator
    Control Group

    Drug: Nimotuzumab · Radiation: radiotherapy

Interventions

  • 1200 mg on Day 1, every 3 weeks (Q3W) for a total of 17 cycles, initiated 3-4 weeks after completion of radiotherapy.

  • 200 mg on Day 1, once weekly (QW) for a total of 7 cycles.

    Also known as: Nimotuzumab injection

  • Radiationradiotherapy

    Intensity-modulated radiation therapy (IMRT) will be administered at a total dose of 60-66 Gy (2 Gy per fraction, 30-33 fractions). A boost to a clearly defined high-risk area may be applied at the investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS

    Time frame: From enrollment until disease recurrence, metastasis, second primary cancer, or death from any cause, assessed up to 3 years after last patient enrolled

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: From enrollment until death from any cause, assessed up to 3 years after last patient enrolled

  2. Locoregional Recurrence-Free Survival (LRRFS)

    Time frame: From enrollment until first locoregional recurrence, assessed up to 3 years after last patient enrolled

  3. Distant Metastasis-Free Survival (DMFS)

    Time frame: From enrollment until first distant metastasis, assessed up to 3 years after last patient enrolled

  4. Change From Baseline in Global Quality of Life Score (EORTC QLQ-C30)

    Assessed using EORTC QLQ-C30 (V3) questionnaires.The EORTC QLQ-C30 is a 30-item validated questionnaire designed to assess the quality of life in cancer patients. It includes five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea/vomiting), a global health status/quality of life scale, and six single items assessing additional symptoms (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All scales and single items are scored on a range from 0 to 100. For the functional scales and global health status scale, higher scores indicate better quality of life or functioning. For the symptom scales and single items, higher scores indicate worse symptoms or greater severity.

    Time frame: Up to 24 months.

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Incidence of Treatment-Emergent Adverse Events (CTCAE 5.0)

    Time frame: From the first dose of nimotuzumab through 30 days after the last dose (approximately 8 weeks total).]

  6. Change From Baseline in Head and Neck-Specific Quality of Life Score (EORTC QLQ-H&N35)

    Assessed using EORTC QLQ-H\&N35 questionnaires.The EORTC QLQ-H\&N35 is a 35-item validated questionnaire specifically designed to assess quality of life in head and neck cancer patients. It includes seven symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality) and eleven single items addressing additional head and neck-specific symptoms (e.g., teeth problems, mouth opening, dry mouth, sticky saliva, coughing, feeling ill, use of painkillers, nutritional supplements, feeding tube, weight loss, and weight gain). All scales and single items are scored on a range from 0 to 100, with higher scores indicating worse symptoms or greater severity.

    Time frame: Up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 51 non-industry phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 67 and three quarters within 121. This study's planned 24 months is below that.

Counting every sponsor, half of 78 studies reached it within 76 months; a quarter within 38 and three quarters within 117.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Mar 3, 2026
StartActual
Mar 4, 2026
Primary completionEst.
Mar 5, 2028
CompletionEst.
Mar 5, 2031
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07445048
Responsible party
Guopei Zhu (Professor, Chief Physician, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University) — Principal investigator
First posted
Mar 3, 2026
Start date
Mar 4, 2026
Primary completion
Mar 5, 2028 (estimated)
Completion
Mar 5, 2031 (estimated)
Last update
Apr 17, 2026

Study contacts

Guopei Zhu
Contact
antica@gmail.com
23211699-5665
Shengjin Dou
Contact
doushengjin@126.com
17521066068

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion